Discoveries regarding the mechanisms of ALDH1 in nonneoplastic diseases have established this family of enzymes as a highly promising therapeutic target for conditions such as NAFLD, PD, OA, and CVDs, where its expression downregulation primarily leads to the loss of protective functions. This evidence concerns the gene ALDH1A1 and Parkinson disease.